@pfeifer1982
Thanks for the input, especially for the numbers, I should have looked
Yes the Expected label population is rather larger.
I've had a another read in light of the info you've provided at the price per dose I used, it's now clear that range of prices I read about from the Decision Resources Group is for the US but using the estimated lowest EU peak sales per year using a 3% royalty the numbers are still much better than I suspected, about double.
You wrote;
"There are similar indications that Cx601 may be able to address (credit to Sanders on seekingalpha.com):
That helps me see why MSB retained the trial to;
- Rectovaginal fistulas in CD,
- Enterocutaneous fistulas in CD,
- Complex anal fistulas in non-CD,
- Intestinal ulcers in CD and
- Intestinal ulcers in Ulcerative Colitis."
"Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease"
Prochymal could address a much larger group of people.
- Forums
- ASX - By Stock
- MSB
- Licensees and MSCs
Licensees and MSCs, page-3
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
95.0¢ |
Change
-0.015(1.55%) |
Mkt cap ! $1.084B |
Open | High | Low | Value | Volume |
96.5¢ | 96.5¢ | 94.5¢ | $2.433M | 2.552M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 72431 | 94.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
95.0¢ | 20225 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 3206 | 0.950 |
4 | 33416 | 0.945 |
4 | 35535 | 0.940 |
4 | 37778 | 0.935 |
5 | 43150 | 0.930 |
Price($) | Vol. | No. |
---|---|---|
0.905 | 13161 | 1 |
0.950 | 4147 | 1 |
0.955 | 15173 | 1 |
0.960 | 26500 | 1 |
0.965 | 42426 | 3 |
Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online